BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 38700729)

  • 1. Re: Percutaneous tibial nerve stimulation for the overactive bladder: A single-arm trial.
    Dai R; Deng C
    Aust N Z J Obstet Gynaecol; 2024 Jun; ():. PubMed ID: 38842050
    [No Abstract]   [Full Text] [Related]  

  • 2. Anticholinergic Burden in Patients Treated for Overactive Bladder: Second-Line Therapy with Tibial Nerve Stimulation as a Solution.
    Satyadev N; Ameen M; Do TH; Wang H
    Int Urogynecol J; 2024 May; ():. PubMed ID: 38700729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcutaneous Tibial Nerve Stimulation in the Management of Overactive Bladder: A Scoping Review.
    Sayner AM; Rogers F; Tran J; Jovanovic E; Henningham L; Nahon I
    Neuromodulation; 2022 Dec; 25(8):1086-1096. PubMed ID: 35688702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
    Rai BP; Cody JD; Alhasso A; Stewart L
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: A prospective randomised controlled trial.
    Sonmez R; Yildiz N; Alkan H
    Ann Phys Rehabil Med; 2022 Jan; 65(1):101486. PubMed ID: 33429090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-inferior and more feasible transcutaneous tibial nerve stimulation in treating overactive bladder: A systematic review and meta-analysis.
    Alomari MS; Abdulhamid AS; Ghaddaf AA; Alshareef KM; Haneef AK; AlQuhaibi MS; Banjar RA
    Int J Urol; 2022 Oct; 29(10):1170-1180. PubMed ID: 35711082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Transcutaneous and Percutaneous Tibial Nerve Stimulation in Bosnian Female Patients with an Idiopathic Overactive Urinary Bladder.
    Zonić-Imamović M; Sinanović O; Imamović M; Muftić M; Janković S; Bazardžanović M
    Acta Med Acad; 2021 Aug; 50(2):235-243. PubMed ID: 34847676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SUFU white paper on overactive bladder anticholinergic medications and dementia risk.
    Zillioux J; Welk B; Suskind AM; Gormley EA; Goldman HB
    Neurourol Urodyn; 2022 Nov; 41(8):1928-1933. PubMed ID: 36066046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome.
    Xia L; Yan H; Sun Y; Zhu Y; Wu Y; Chen Z; Su S
    Medicine (Baltimore); 2021 Nov; 100(45):e27745. PubMed ID: 34766587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis.
    Pieper NT; Grossi CM; Chan WY; Loke YK; Savva GM; Haroulis C; Steel N; Fox C; Maidment ID; Arthur AJ; Myint PK; Smith TO; Robinson L; Matthews FE; Brayne C; Richardson K
    Age Ageing; 2020 Oct; 49(6):939-947. PubMed ID: 32603415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Implantable PTNS Devices.
    Vollstedt A; Gilleran J
    Curr Urol Rep; 2020 May; 21(7):28. PubMed ID: 32462381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study.
    Coupland CAC; Hill T; Dening T; Morriss R; Moore M; Hippisley-Cox J
    JAMA Intern Med; 2019 Aug; 179(8):1084-1093. PubMed ID: 31233095
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.